Interstitial Lung Disease Research Pipeline

According to NIH funding data, a very large amount of public research funding has been directed toward Interstitial Lung Disease, which signals that this condition has attracted serious scientific attention from one of the world's largest medical research bodies. However, the direction of that funding has been falling year on year, meaning the level of investment is declining rather than growing. For patients, this pattern suggests that while ILD has been a significant research priority, there may be less momentum behind new publicly funded studies in the near term.

Registry data shows that clinical trials are active at both early and late stages of development, which is an encouraging sign for the overall state of ILD research. Early stage trials, such as Phase 1 and Phase 2 work, suggest researchers are still exploring new approaches, while later stage trials indicate that some treatments have progressed far enough to be tested on larger groups of patients for effectiveness. Together, this mix of trial activity suggests the field is mature in some areas while still breaking new ground in others.

For Australian patients, the picture around local availability is currently unclear based on the data tracked here. No TGA approval is recorded for treatments in this area, meaning no regulatory approval through Australia's medicines regulator is captured in the current data, and no PBS listing is recorded to indicate subsidised access through Australia's public medicines scheme. This does not necessarily mean no options exist, but it does mean Australian patients should speak directly with their specialist about what is currently accessible to them in a local clinical context.

This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.